CORDIS
EU research results

CORDIS

English EN
Mid-infrared arthroscopy innovative imaging system for real-time clinical in depth examination and diagnosis of degenerative joint diseases

Mid-infrared arthroscopy innovative imaging system for real-time clinical in depth examination and diagnosis of degenerative joint diseases

Objective

MIRACLE will take towards commercialization the first mid-infrared (MIR) arthroscopy probe for in-depth evaluation of articular cartilage enabling early diagnosis of degenerative joint diseases such as osteoarthritis (OA). The proposed device is intended for use during a minimally invasive surgery (arthroscopy). Currently, the surgeon’s decision-making is based on visual inspection and manual probing of the cartilage tissue which is highly subjective and of poor repeatability. Untreated or not-correctly treated joint injury will most likely progress towards OA, which will lead to joint pain, movement limitation, joint failure, and ultimately disability and joint replacement. OA constitutes a major challenge for the health systems and affects 242 million people globally. Moreover, OA is highly prevalent in Europe with an estimated 19.7-42.3% in the elderly population. MIRACLE concept is to access the biochemical on articular cartilage, which precedes OA. The feasibility of this approach as a diagnostic method has been demonstrated by MIRACLE consortium (TRL4). MIRACLE has also prototyped a MIR-probe with potential use for diagnostics (TRL4). By technology development reaching TRL 6-7, MIRACLE will bring to the arthroscopy market the first MIR-based probe providing an unique, accurate and quantitative diagnostic tool for the orthopedic surgeon. This will be achieved combining three novel photonics components: (i) a quantum cascade laser array tailored to biodiagnostics, (ii) an on-chip beam combiner for efficient radiation coupling, and (iii) MIR sensing probe for imaging. These components will be integrated in a medical device to be placed in the arthroscopy market (valued at $4 billion in 2015). In addition to add value to the European medical equipment industry, MIRACLE strives towards cost reduction of OA patients (currently costs/patient/year €10,452) contributing to more affordable public health care and promoting wellbeing in the European ageing population.

Coordinator

OULUN YLIOPISTO

Address

Pentti Kaiteran Katu 1
90014 Oulu

Finland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 146 325

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAET ULM

Germany

EU Contribution

€ 842 500

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 585 856,25

NORGES MILJO-OG BIOVITENSKAPLIGE UNIVERSITET

Norway

EU Contribution

€ 538 431,25

POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA

Finland

EU Contribution

€ 173 750

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 293 376,25

NANOPLUS NANOSYSTEMS AND TECHNOLOGIES GMBH

Germany

EU Contribution

€ 797 204,63

OPTOPRECISION GMBH

Germany

EU Contribution

€ 470 312,50

IRIS TECHNOLOGY SOLUTIONS, SOCIEDAD LIMITADA

Spain

EU Contribution

€ 352 450

ART PHOTONICS

Germany

EU Contribution

€ 310 187,50

INEB-INSTITUTO NACIONAL DE ENGENHARIA BIOMEDICA

Portugal

EU Contribution

€ 439 375

ASOCIACION ESPANOLA DE NORMALIZACION

Spain

EU Contribution

€ 77 500

PHOTONICS FINLAND

Finland

EU Contribution

€ 106 367,50

Project information

Grant agreement ID: 780598

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    30 June 2021

Funded under:

H2020-EU.2.1.1.

  • Overall budget:

    € 6 960 845

  • EU contribution

    € 6 133 635,88

Coordinated by:

OULUN YLIOPISTO

Finland